Skip to content

Furosemide Stress Test as a Predictor of Tubular Function in Chronic Kidney Disease

Furosemide Stress Test as a Predictor of Tubular Atrophy and Interstitial Fibrosis in Patients With Chronic Kidney Disease

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02417883
Acronym
FST-IFTA
Enrollment
100
Registered
2015-04-16
Start date
2015-04-30
Completion date
2017-04-30
Last updated
2015-04-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease

Keywords

Furosemide, Interstitial Fibrosis

Brief summary

In kidney diseases, tubule-interstitium has become much more relevant, as formerly only the glomerulus was considered to have the main importance. Kidney's tubular atrophy and interstitital fibrosis is now recognized as long term prognostic value. We aim to evaluate the function of the kidney's tubule-interstitium through furosemide excretion after intravenous administration of this drug, and correlate the rate of excretion of furosemide with interstitial fibrosis findings in scheduled kidney biopsy for patients with chronic kidney disease.

Detailed description

All patients scheduled for kidney biopsy will be invited to participate in a standard isovolemic furosemide stress test before the biopsy procedure. The latter will consist in 1.5 miligrams per kilogram of weight of intravenous furosemide administration, with urinary output follow up and measurement. The urinary output will be replaced intravenously with normal saline to avoid dehydration and/or hypotension. A standard 5ml sample of blood will be taken before the test and aliquots of urine before and after furosemide administration will be frozen. After completion of the formely mentioned test, patients will proceed to their scheduled kidney biopsy along with interventions considered appropiate by their attending physician. Kidney biopsy sample will be examined by histopathology service and the degree of interstitial fibrosis will be described. The degree of fibrosis will be correlated with the degree furosemide excretion and urinary output.

Interventions

DRUGFurosemide

Evaluate urinary excretion rate fo furosemide

Sponsors

Instituto Nacional de Cardiologia Ignacio Chavez
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Accept to participate (informed consent) * Legal age or older * An estimated glomerular filtration rate greater than 15ml/min/1.73m2, calculated by CKD-EPI.

Exclusion criteria

* Known Alergic reaction to furosemide * Contraindication to kidney biopsy * Patient already in renal replacement therapy

Design outcomes

Primary

MeasureTime frameDescription
Urinary Output6 hoursCuantify urinary output after furosemide administration

Secondary

MeasureTime frameDescription
Furosemide excretion rate6hrsCuantify furosemide excretion in urine
Interstitial Fibrosis3 daysMeasure interstitial fibrosis in kidney biopsy

Countries

Mexico

Contacts

Primary ContactMagdalena Madero, MD
madero.magdalena@gmail.com+55-5573-2911
Backup ContactCarlos A Garza, MD
gza.carlos@gmail.com+55-5573-2911

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 18, 2026